We conducted a phase II study (ClinicalTrials.gov Identifier: NCT02639065) evaluating the efficacy and safety of PD-L1 inhibitor durvalumab in patients with locally advanced esophageal and GEJ AC....Higher PD-L1 expression may have a correlation with the efficacy of durvalumab in this setting...median RFS and OS were numerically superior among patients with PD-L1 CPS ≥10 compared to <10 (median RFS: not reached vs. 16.8 months, p = 0.1825; and median OS: not reached vs. 30.7 months, p = 0.1356). Using CPS ≥1 as a cutoff, patients with PD-L1 positive disease had numerically superior RFS (median RFS: 40.4 vs. 15 months, p = 0.0727) and superior OS that was clinically as well as statistically significant (median OS: 40.4 vs. 25.0 months, p = 0.0132).